Potential of Inaccurate Cefiderocol Susceptibility Results: a CLSI AST Subcommittee Advisory-Reference-Cited by-同舟云学术

Potential of Inaccurate Cefiderocol Susceptibility Results: a CLSI AST Subcommittee Advisory

Published:2023-04-20 Issue:4 Volume:61 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Simner Patricia J.¹²^ORCID,Palavecino Elizabeth L.³,Satlin Michael J.⁴^ORCID,Mathers Amy J.⁵,Weinstein Melvin P.⁶,Lewis James S.⁷^ORCID,Humphries Romney⁸^ORCID

Affiliation:

1. Department of Pathology, Division of Medical Microbiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

2. Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

3. Department of Pathology, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA

4. Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, USA

5. Department of Medicine and Pathology, University of Virginia School of Medicine, Charlottesville, Virginia, USA

6. Department of Pathology & Laboratory Medicine, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA

7. Departments of Pharmacy & Infectious Diseases, Oregon Health & Science University, Portland, Oregon, USA

8. Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/jcm.01600-22

Reference12 articles.

1. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli

2. The Role of Iron and Siderophores in Infection, and the Development of Siderophore Antibiotics

3. In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria

4. Clinical and Laboratory Standards Institute. 2022. Performance standards for antimicrobial susceptibility testing; Thirty-Second Informational Supplement., M100-S32. CLSI, Wayne, PA.

5. Clinical and Laboratory Standards Institute. 2021. 2021 Winter AST summary minutes. https://clsi.org/meetings/ast-file-resources/.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections;JAC-Antimicrobial Resistance;2024-09-03

2. In vivo emergence of cefiderocol and ceftazidime/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime/avibactam -based therapies;Diagnostic Microbiology and Infectious Disease;2024-09

3. Should we, and how to, optimize cefiderocol administration during severe nosocomial pneumonia due to carbapenem-resistant Acinetobacter baumanii? A viewpoint;Journal of Global Antimicrobial Resistance;2024-09

4. Cefiderocol heteroresistance associated with mutations in TonB-dependent receptor genes in Pseudomonas aeruginosa of clinical origin;Antimicrobial Agents and Chemotherapy;2024-08-07

5. Successful Treatment of Carbapenem-Resistant Acinetobacter baumannii Meningitis With Sulbactam-Durlobactam;Clinical Infectious Diseases;2024-04-17